Why This Matters
Clinical and regulatory catalysts can define valuation, financing options, and investor attention for small-cap biotechnology companies.
Phase 3 Readouts
Phase 3 Readouts are among the catalyst types tracked across undercovered healthcare companies. This public page focuses on timing, company, asset, and broad confidence labels.
| Company | Ticker | Catalyst | Timing | Asset | Confidence |
|---|---|---|---|---|---|
| BioVie Inc | BIVI | Clinical Trial Completion | 2026-08 | NE3107 | Low |
| Ensysce Biosciences Inc | ENSC | Clinical Trial Completion | 2026-08 | PF614 capsule | Low |
| CDT Equity Inc | CDT | Clinical Trial Completion | 2026-10-20 | Litifilimab | Low |
| Gossamer Bio Inc | GOSS | Clinical Trial Completion | 2026-12 | Seralutinib | Low |
| Intensity Therapeutics Inc | INTS | Clinical Trial Completion | 2027-01 | Pirtobrutinib | Low |
| Astria Therapeutics | ATXS | Clinical Trial Completion | 2027-03 | Navenibart | Low |
| Tempest Therapeutics Inc | TPST | Clinical Trial Completion | 2027-07 | Pentosan Polysulfate Sodium twice weekly | Low |
| Cadrenal Therapeutics Inc | CVKD | FDA Meeting | Timing not specified | CAD-1005 | Low |
| Dare Bioscience Inc | DARE | Interim Data | July 2025 | n/a | Low |